- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03856333
Cognitive Exercise Therapy Approach Scale in Patients With Chronic Neck Pain
Determining the Validity, Reliability and Responsiveness of Cognitive Exercise Therapy Approach Scale in Patients With Chronic Neck Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Famagusta, Cyprus
- Özge Şahin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals aged between 18-65 years
- Neck pain VAS out of 3 and above which individuals
- Individuals who have neck pain for more than 3 months
Exclusion Criteria:
- Patients with previous neck surgery history
- Not willing to participate in the study
- Attract trouble understanding for filling scale
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: traditional treatment
30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
|
exercises, physical agents
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Exercise Therapy Approach Scale (BETY)
Time Frame: Change from the baseline will be assesed at the first week and at the third week.
|
The biopsychosocial process associated with the neck pain will be evaluated by the 'Cognitive Exercise Therapy Approach Scale'. The scale consists of 30 items. The scale was scored using a 5-point Likert system. Every question; No in no time: 0, Yes rarely: 1, Yes sometimes: 2, Yes often: 3, Yes is always scored as 4: and gives a total score of 30 items. High score means low biopsychosocial status assessment is "bad |
Change from the baseline will be assesed at the first week and at the third week.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neck Disability Index (NDI)
Time Frame: At the beginning and 2 weeks after the start of treatment
|
It is used to assess the disability caused by neck pain.
The index consists of 10 chapters including the severity of pain, personal care, lifting, reading, headache, concentration, working life, driving, sleep and leisure time.
There are 6 responses for each section, 0 (no pain and no functional limitation) and 5 (worst pain and maximum limitation).
There was no apology between 0-4 points in the NDI, mild disability between 5-14 points, moderate disability between 15-24 points, severe apology between 25-34 points and full disability over 35 points .
The Turkish validity and reliability study was conducted by Aslan et al.
|
At the beginning and 2 weeks after the start of treatment
|
|
Arm, Shoulder and Hand Problems Questionnaire (DASH)
Time Frame: At the beginning and 2 weeks after the start of treatment
|
It is a scale used to evaluate the functional disability associated with upper extremity.
The scale consists of three parts.
DASH has a total of 30 questions and includes 8 questions for people who are engaged in work and social activities.
In case of not answering more than 3 questions, the questionnaire is considered invalid.
Response options in scale are between 1 and 5. Scoring for each section is calculated as 0-100.
High scores indicate serious activity limitations .
The scale is valid, reliable and sensitive to changes.
The Turkish cultural adaptation was also made and the scale was found to be valid and reliable for the Turkish version.
|
At the beginning and 2 weeks after the start of treatment
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: At the beginning and 2 weeks after the start of treatment
|
The area of use of the scale is not to diagnose, but to reveal the depression and anxiety associated with existing diseases.
It has been widely used in a variety of somatic, psychiatric and primary care populations and in many chronic diseases such as musculoskeletal, cancer, end-stage renal disease, and has been found to be able to measure depression and anxiety significantly .
It is a 14-item scale consisting of seven anxiety-related subscales (HADS-A) and depression subscale (HADS-D).
Each question is scored between 0 and 3 and is interpreted according to the total score.
Although the total score indicates the increased level of anxiety and depression, it can be interpreted as being 'normal' between 0-7, being between 8-10, 'borderline normal', and between 11-21 being 'abnormal'.
The Turkish validity and reliability study was conducted by Aydemir et al.
|
At the beginning and 2 weeks after the start of treatment
|
|
Short Form-36 (SF-36)
Time Frame: At the beginning and 2 weeks after the start of treatment
|
This questionnaire, which evaluates the quality of life of the person, consists of 36 questions on eight sub-scales: physical function, physical role restriction, emotional role restriction, body pain, social function, mental health, vitality, and general health.
The scores are scored separately for each subscale and the scores range from 0 to 100. 100 points indicate good health status, while 0 points indicate poor health status .
The reliability and validity study of Turkish by Koçyiğit et al .
|
At the beginning and 2 weeks after the start of treatment
|
|
Visual Analogue Scale (VAS)
Time Frame: At the beginning, and 2 weeks after the start of treatment
|
The pain intensity of individuals was questioned by Vizel Analog Scale.
VAS is a method used in numerical form to quantify non-measured values.
It is often preferred because it can be easily applied and repeated in a short time.
The parameter to be evaluated in a horizontal line of 10 centimeters is written to define both endpoints and the patient is asked to mark the appropriate point for the parameter evaluated on this 10-centimeter line.
The severity of the patient's pain is determined by measuring the length of the distance from the point of pain to the point determined by the patient
|
At the beginning, and 2 weeks after the start of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Özge Şahin, EMU
- Study Director: Sevim Öksüz, PhD, EMU
- Study Director: Ender Angın, PhD, EMU
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OZ 1313
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment
-
University of PadovaUniversity of Turin, ItalyNot yet recruiting
-
Psychiatric Centre RigshospitaletAstraZenecaTerminatedMedical Treatment | Antipsychotic Treatment | Quality AssuranceDenmark
-
Vilniaus Implantologijos Centro (VIC) KlinikaInstitut Straumann AGActive, not recruitingSingle Implant; Immediate Implant Treatment; Early Implant TreatmentLithuania
-
Sunnybrook Health Sciences CentreRecruitingTreatment-Resistant Depression | Treatment-resistant Depression (TRD)Canada
-
Chinese PLA General HospitalNot yet recruitingTreatment for Advanced Colorectal Cancer | Treatment for Advanced Pancreatic Cancer
-
Dr. Stavroula RakitziActive, not recruitingTreatment Resistant Schizophrenia | Treatment Resistant Bipolar DisorderGreece
-
NeuroRx, Inc.neurocare group AG; Zeta Surgical, Inc.; HOPE Therapeutics, Inc.Not yet recruitingTreatment Resistant Depression | Treatment Resistant Depression (TRD)United States
-
Zagazig UniversityNot yet recruiting
-
Ajman UniversityCompletedTreatmentUnited Arab Emirates
-
Nanjing University School of MedicineCompleted
Clinical Trials on Assigned Interventions
-
Riphah International UniversityCompletedHealthy Young AdultsPakistan
-
Universiti Putra MalaysiaRecruiting
-
Yeditepe UniversityNot yet recruitingMelorheostosisTurkey (Türkiye)
-
Hospital for Special Surgery, New YorkNot yet recruitingGut Microbiota | Inflammatory Markers | Total Knee Arthroplasty RevisionUnited States
-
Pamukkale UniversityNot yet recruitingBipolar Disorder | Motivational InterviewsTurkey
-
Istanbul UniversityCompletedStructured Feedback | Clinical Decision-Making, Anxiety, Self-Confidence | Undergraduate Nursing Education | Learning MotivationTurkey
-
Colorado State UniversityCompleted
-
Suleyman Demirel UniversityNot yet recruiting
-
Future University in EgyptNot yet recruitingDental Caries | DME | Dental | Deep Margin Elevation
-
University of Illinois at ChicagoRecruitingHypertension | Obesity | Nutrition, HealthyUnited States